CDK4 and hepatocellular carcinoma: Accordingly, our recent findings demonstrated that HCC cell lines harboring CDKN2A/ARF gene loss and expressing a functional Rb protein were sensitive to palbociclib, and proved the efficacy of CDK4/6 inhibition in combination with regorafenib, thus suggesting a novel approach for the treatment of HCC patients (18).